What is it about?
This review aimed to summarize designs and endpoints of 65 RCTs for cancer cachexia in the past 16 years and seek clinically relevant PROs for future clinical trials.
Featured Image
Photo by David Edelstein on Unsplash
Why is it important?
There is an urgent need to reconsider the clinically relevant endpoints of clinical trials for cancer cachexia that simultaneously meet the demands from patients, researchers, and regulatory authorities. The true endpoint in trials for cancer cachexia may be the expansion of active life with better QOL. Although the classical endpoint of increasing body mass would be an important outcome, it may not always contribute as a true endpoint.
Perspectives
An optimal measurable endpoint should be identified, and a better combination of pharmacological and nonpharmacological interventions be established to improve functional prognosis in patients with this long‑standing disease.
MD. PhD. Tateaki Naito
Shizuoka Cancer Center
Read the Original
This page is a summary of: Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia, Asia-Pacific Journal of Oncology Nursing, January 2019, Medknow,
DOI: 10.4103/apjon.apjon_68_18.
You can read the full text:
Resources
Contributors
The following have contributed to this page
